Matches in Nanopublications for { ?s ?p "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP379353.RAf9FZpizzuh7vZ1c6uoR88FgjJXhU-dGZV0ZVzyEfRlQ130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379353.RAf9FZpizzuh7vZ1c6uoR88FgjJXhU-dGZV0ZVzyEfRlQ130_provenance.
- assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP908187.RAIi4GXKZ4TxiIqbwKqtd_VQA6kqyVwSdy7xoUZP5YmTc130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP908187.RAIi4GXKZ4TxiIqbwKqtd_VQA6kqyVwSdy7xoUZP5YmTc130_provenance.
- NP618193.RATZMuEQZkxdccLzOk_4bByJV6aipJqZwCAnxS2qQJ-Kw130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618193.RATZMuEQZkxdccLzOk_4bByJV6aipJqZwCAnxS2qQJ-Kw130_provenance.
- NP801066.RArhf0fx0vRxml8ToYk6gv4KtshxH2aivHIJhtuczTlYo130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801066.RArhf0fx0vRxml8ToYk6gv4KtshxH2aivHIJhtuczTlYo130_provenance.
- NP618192.RAlCKdRHhYfoYIZxTDueYj0X-k4HOmSEDNLGgwgaKXVSI130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618192.RAlCKdRHhYfoYIZxTDueYj0X-k4HOmSEDNLGgwgaKXVSI130_provenance.
- NP801071.RAE40Bu0IbZHqoGXSLQI-9d0hetrq3wLLbkvTGXVA1BZs130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801071.RAE40Bu0IbZHqoGXSLQI-9d0hetrq3wLLbkvTGXVA1BZs130_provenance.
- NP618191.RAL0UJbxgntv0ZTFZS37NDBee58TfjvinSUg8CZLNJWbs130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618191.RAL0UJbxgntv0ZTFZS37NDBee58TfjvinSUg8CZLNJWbs130_provenance.
- NP801039.RA_K9DpMyMNiFr89B6EbwdMkporeUpcY5-OlslyuwCyDo130_assertion description "[The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801039.RA_K9DpMyMNiFr89B6EbwdMkporeUpcY5-OlslyuwCyDo130_provenance.